65,437 trials
Varicose Veins
Primary: Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score) — 2.13; 4.63; 5.68; 4.87 units on a scale — p==0.0001
Neurogenic Orthostatic Hypotension · Non-Diabetic Autonomic Neuropathy · Multiple System Atrophy
Primary: Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ) — 0.57; 0.90 units on a scale — p=0.438
Pregnancy · Drug Abuse
Primary: Fetal Heart Rate — 142.34 beats per minute
Hunter Syndrome
Primary: Number of Serious Adverse Event (SAE) — 0; 8; 3; 3 events
Breast Reconstruction
Primary: Investigator Satisfaction Following Use of SERI® Surgical Scaffold at 6 Months — 9.4 units on a scale
Myopia · Astigmatism · Refractive Error
Primary: Percentage of Lenses With Axis Orientation ≤ 10 Degrees From Ideal Location After 3 Minutes of Wear — 24.5; 46.9; 36.7 percentage of lenses
Breast Cancer
Primary: Progression Free Survival — 103; 81 Days
General Anesthesia · Propofol Target-controlled Infusion · Thoracic Epidural Anesthesia
Primary: Propofol Effect-site Concentration — 1.76; 1.14; 1.09; 1.04 ug/ml
Diabetes Mellitus, Type 2
Primary: Glucagon Concentration (Nanomoles Per Liter [Nmol/L]) During the Hypoglycemic Periods of the Glucose Clamp Procedure — 0.03780; 0.03805; 0.03780; 0.03780 Nanomoles per…
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — -0.83; -0.52 Percentage of HbA1c in the blood — p=<0.0001
Meningioma
Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients
Diabetes Mellitus, Type 2
Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104 — 0.27; -0.28; -0.36; -0.63 Percentage of HbA1c in the blood — p=<0.0001
Cancer
Primary: Progression-free Survival (PFS) as Assessed by the Investigator — 6.9; 2.7 Months — p=<0.0001
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Orthostatic Hypotension Questionnaire Score (OHQ) — -1.83; -0.93 units on a scale — p=0.003
Influenza
Primary: Number of RA Participants in the 2011-2012 Season Who Achieved Seroconversion at Day 21 Against Each of the 3 Specific Influenza Strains in Vaccine the Participant…